Astrazeneca: FASENRA Enabled Patients To Taper Off Oral Corticosteroids While Preventing Relapses
February 23, 2024
February 23, 2024
WILMINGTON, Delaware, Feb. 23 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
MANDARA Phase III data published in New England Journal of Medicine show remission is an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with FASENRA
* * *
Positive results from the MANDARA Phase III trial for FASENRA(R) (benralizumab) in patients with EGPA were published in the New England Journal of Medic . . .
* * *
MANDARA Phase III data published in New England Journal of Medicine show remission is an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with FASENRA
* * *
Positive results from the MANDARA Phase III trial for FASENRA(R) (benralizumab) in patients with EGPA were published in the New England Journal of Medic . . .